ALKS - Alkermes plc Ordinary Shares -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Alkermes plc Ordinary Shares
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
IPO Date: August 1, 1991
Sector: Healthcare
Industry: Biotech
Market Cap: $6.95B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.53 | 1.99%
Avg Daily Range (30 D): $0.76 | 1.70%
Avg Daily Range (90 D): $0.93 | 1.95%
Institutional Daily Volume
Avg Daily Volume: 1.1M
Avg Daily Volume (30 D): 1.48M
Avg Daily Volume (90 D): 1.48M
Trade Size
Avg Trade Size (Sh.): 112
Avg Trade Size (Sh.) (30 D): 68
Avg Trade Size (Sh.) (90 D): 64
Institutional Trades
Total Institutional Trades: 14,931
Avg Institutional Trade: $2.69M
Avg Institutional Trade (30 D): $4.98M
Avg Institutional Trade (90 D): $5.24M
Avg Institutional Trade Volume: .09M
Avg Institutional Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $5.88M
Avg Closing Trade (30 D): $19.34M
Avg Closing Trade (90 D): $21.99M
Avg Closing Volume: 191.64K
 
News
Oct 2, 2026 @ 8:54 AM
Global Substance Use Disorder Treatment Market Ana...
Source: Researchandmarkets.Com
Sep 22, 2026 @ 3:15 PM
Alkermes Posts Positive Data From Phase I ADHD Stu...
Source: Na
Jun 8, 2026 @ 5:00 PM
Alcohol Use Disorder Market Set to Expand at a 12....
Source: Delveinsight
Feb 23, 2026 @ 3:26 PM
Viridian Therapeutics Stock Up 75%, but One Fund J...
Source: Jonathan Ponciano
Feb 23, 2026 @ 3:18 PM
Spyre Therapeutics Stock Surges This Past Year as ...
Source: Jonathan Ponciano
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $.4 $ $-.4
Diluted EPS $.38 $ $-.4
Revenue $1.67B $496.01M $392.91M
Gross Profit $1.41B $397.9M $331.33M
Net Income / Loss $66.12M $.5M $-66.48M
Operating Income / Loss $117.26M $18.35M $-48.28M
Cost of Revenue $257.49M $98.11M $61.58M
Net Cash Flow $-9.67M $159.98M $-768.22M
PE Ratio    
Splits
May 15, 2000 2:1